SDShuyue Dong

Shuyue Dong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shuyue Dong has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Jinxi Meng

    Hematology Department, Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education Beijing Children's Hospital, National Center for Children's Health, Capital Medical University Beijing China

    5 shared publications
  • Runhui Wu

    Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

    5 shared publications
  • Xiaoling Cheng

    Department of Pharmacy, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

    5 shared publications
  • Zhifa Wang

    Hematology Center National Key Discipline of Pediatrics (Capital Medical University) Beijing China

    5 shared publications
  • Jingyao Ma

    Hematology Center National Key Discipline of Pediatrics (Capital Medical University) Beijing China

    4 shared publications
  • Zhenping Chen

    Cell and Gene Therapy Laboratory, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health

    4 shared publications

Latest Publications

  • Daratumumab in Pediatric Chronic Refractory Primary Immune Thrombocytopenia ( ITP ): Rapid Platelet Recovery, Sustained Response, and Immune Reconstitution Dynamics

    by Yu Hu, Hui Chen, Zhifa Wang, Jingyao Ma, Shuyue Dong, Xi Lin, Xiaoling Cheng, James B. Bussel, Zhenping Chen, Runhui Wu


  • Machine learning to forecast rituximab responses for paediatric immune thrombocytopenia: Forging a path towards personalized medical care

    by Jingyao Ma, Chang Cui, Juntao Ouyang, Zheyan Lin, Xi Lin, Yu Hu, Zhifa Wang, Shuyue Dong, Jinxi Meng, Wensheng Zhang, et al.

    Summary: Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by decreased platelet counts and increased bleeding risk. Although paediatric ITP often resolves spontaneously, some children do not respond to first‐line treatments, thus requiring rituximab as a second‐line therapy to reduce bleeding risks and corticosteroid exposure. Currently, there is no reliable method to predict the efficacy of rituximab. Our study aimed to develop a machine learning (ML) model to predict the initial response to rituximab in these patients. We analysed data from 156 paediatric ITP patients treated at Beijing Children's Hospital between 2020 and 2023 and identified 25 key predictive features. Among the four evaluated ML models, the multilayer perceptron model exhibited the highest predictive accuracy. SHapley Additive exPlanations analysis revealed that antinuclear antibody titre, thyroglobulin antibody, corticosteroid response and bleeding severity were significant positive predictors, while thyroid peroxidase antibody, CD3+ CD4+ IL‐17+ T cells and the duration of disease before rituximab treatment were negatively associated with treatment responses. This ML model could be used to predict rituximab responses in paediatric ITP, which is expected to optimize treatment strategies and improve patient outcomes.


  • Long‐term efficacy and safety of avatrombopag in Chinese children with primary immune thrombocytopenia: A real‐world observational study

    by Nan Wang, Zhifa Wang, Jingjing Liu, Yu Hu, Shuyue Dong, Hui Chen, Jinxi Meng, Jingyao Ma, Zhenping Chen, Xiaoling Cheng, et al.

    Summary: Avatrombopag is a newly approved thrombopoietin receptor agonist for second‐line treatment of chronic immune thrombocytopenia (ITP) in adults. Our previous study showed its efficacy and safety in a small sample of paediatric ITP patients. However, large samples and long‐term data are still lacking. Children diagnosed with ITP and treated with avatrombopag for at least 4 weeks were enrolled. In 94 ITP patients with a median age of 7.43 (interquartile range (IQR), 4.82, 10.80) years, the median effective dose was 10 (IQR, 10, 20) mg for children under 6 years old and 20 (IQR, 20, 40) mg for children under 18 years old. The overall response was achieved in 72.3% (68/94) and 73.4% (58/79) of patients within 4 weeks and 12 weeks. The sustained response at 24 weeks and 48 weeks were 62.3% (33/53) and 51.6% (16/31) respectively. The occurrence of bleeding events, rescue therapy and concomitant ITP medication decreased during the follow‐up period. For safety, thrombocytosis (platelet count ≥400 × 109/L) was the most frequent adverse event (AE) observed in 44 children 97 times. Long‐term treatment with avatrombopag in ITP children showed a rapid and sustained platelet response and good bleeding control without significant or new AEs.


  • Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring

    by Shuyue Dong, Zhifa Wang, Nan Wang, Jingyao Ma, Jinxi Meng, Zhenping Chen, Runhui Wu, Xiaoling Cheng

    Summary: There are variations in individual eltrombopag concentrations that may impact efficacy and adverse drug reactions (ADRs) in paediatric immune thrombocytopenia (ITP). To solve this problem, we tailored the eltrombopag dosage refer to concentration, then followed up to assess concentration value in paediatric ITP. This is a single‐centre, prospective, observational study. The eltrombopag dosage was adjusted, and children were divided into three groups: the maintenance, discontinuation, and increase groups. Concentration and other data were compared to explore concentration value in guiding the individualized treatment of paediatric ITP. Thirty‐nine patients were enrolled, including 23 in the maintenance group, 3 in the discontinued group and 13 in the increase group. 3 patients discontinued eltrombopag due to ADRs, which was significantly higher than patients in the maintenance group (t = 3.606, p = 0.001). In all, 13 patients increased their dosage due to poor response, whose concentration and platelet count were significantly lower than patients in the maintenance group (t = 2.461, p = 0.019; t = 4.633, p < 0.001). Two months after the increase, the number of patients reaching CR and R respectively increased by 2 and 3, while the median platelet count was significantly raised (Z = −2.411, p = 0.016). Concentration could be used as a reference index for the individualized treatment of eltrombopag in paediatric ITP.


  • Open Access

    Spotlight on eltrombopag concentration in pediatric immune thrombocytopenia: A single‐center observational study in China

    by Shuyue Dong, Zhifa Wang, Nan Wang, Jingyao Ma, Jinxi Meng, Yixin Sun, Xiaoling Cheng, Runhui Wu

    Importance: Eltrombopag has been recommended for pediatric immune thrombocytopenia (ITP). Response and adverse drug reactions (ADRs) varied widely between individuals, even at the same dose of eltrombopag. The appropriate eltrombopag concentration in ITP has not been reported.Objective: This study aims to explore the appropriate eltrombopag concentration in pediatric ITP.Methods: This was a single‐center, prospective cohort study. Children diagnosed with refractory persistent/chronic ITP and platelet count < 30×109/L were treated with eltrombopag and followed up for at least 2 months. Concentration was detected by high‐performance liquid chromatography‐mass spectrometry at least 2 weeks after eltrombopag. The clinical characteristics‐concentration, concentration‐response, and concentration‐ADRs were analyzed.Results: A total of 30 patients were enrolled, comprising 13 males and 17 females, with a median age of 72 (45‒94) months. The median dose and concentration were 1.39 (1.09‒1.56) mg/kg and 2.70 (2.25‒4.13) mg/L, respectively. Of the enrolled patients, 14 responded to treatment, whereas 16 did not. Additionally, five experienced adverse drug reactions. No linear correlation was observed between eltrombopag concentration and clinical characteristics. The concentration was lower in the response group than in the nonresponse group, but there was no significant difference (t = 0.755, P = 0.457). Patients who experienced ADRs had a higher concentration than those without ADRs (t = 2.538, P = 0.017). The area under the receiver operating characteristic curve of ADRs was 0.78 (95% confidence interval: 0.56‒1.00). Youden's index identified the cutoff point as 4.33 mg/L, with a sensitivity of 88% and a specificity of 60%. Logistic regression analysis demonstrated that a higher platelet count before eltrombopag predicted a favorable response.Interpretation: Eltrombopag proves efficacious and well‐tolerated for treating pediatric ITP. However, prolonged and high‐dose administration may increase the likelihood of ADRs. Thus, examining the appropriate eltrombopag concentration assists in directing individualized management of pediatric ITP.


  • Sustained response off treatment in eltrombopag for children with persistent/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China

    by Zhifa Wang, Lijuan Wang, Yan Liu, Jinxi Meng, Shuyue Dong, Jingyao Ma, Yu Hu, Zhenping Chen, Xiaoling Cheng, Runhui Wu

    Summary: Eltrombopag (ELT) is effective and safe in adult persistent/chronic immune thrombocytopenia (p/cITP); a proportion could achieve a sustained response off treatment (SRoT); however, data on children are lacking. We attempted to analyse SRoT of ELT in children with p/cITP in this study. A multicentre retrospective observational study was performed in November 2022 for children with p/cITP who used ELT alone for >2 months between January 2017 and November 2021. Clinical data of pre‐, during and post‐ELT were collected. SRoT was defined as maintaining a platelet count of ≥30 × 109/L without rescue therapy for at least 6 months off ELT. There were 143 patients enrolled; 69.2% (99/143) achieved an overall response of 43.3% and 25.9% achieved complete response (CR) and response (R). Among the 35 patients analysed from whom ELT was withdrawn, 71.4% (25/35) showed SRoT after discontinuing ELT without additional ITP therapy, with a median follow‐up of 0.94 (range, 0.53–3.8) years, equal to 17.5% (25/143) in all patients treated with ELT. Compared with the patients with relapse (n = 10), the SRoT patients (n = 25) had a higher rate of CR (80% [20/25] vs. 40% [4/10]), shorter interval time from initiation to taper (6.4 months vs. 9.4 months), longer time from taper to withdrawal (1.1 years vs. 0.3 years) and a longer duration of ELT treatment (1.6 years vs. 0.5 years) with p < 0.05. Patients who achieved CR could attain SRoT more easily (p = 0.02). ELT had a response in 69.2% of children with p/cITP and 17.5% of them attained SRoT with good tolerance. The patients who achieved CR and began ELT treatment as early as possible, with a longer treatment duration and slower tapering, had a higher probability of SRoT.